STOCK TITAN

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Spectrum Pharmaceuticals is set to engage investors through two upcoming presentations at major healthcare conferences in New York. The Jefferies Healthcare Conference will feature a fireside chat on June 9, 2022, from 1 to 1:25 p.m. ET, followed by a presentation at the JMP Securities Life Sciences Conference on June 16, 2022, from 9 to 9:25 a.m. ET. Both events will be accessible via live webcast on the company’s Investor Relations webpage. Spectrum focuses on developing innovative oncology therapies, with a late-stage pipeline designed to meet significant medical needs.

Positive
  • None.
Negative
  • None.

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences:

  • A fireside chat presentation at the Jefferies Healthcare Conference in New York from 1 to 1:25 p.m. ET on Thursday, June 9, 2022; and,
  • A fireside chat presentation at the JMP Securities Life Sciences Conference in New York from 9 to 9:25 a.m. ET on Thursday, June 16, 2022.

A live webcast of each presentation will be available on the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after the live event.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

Notice Regarding Forward-looking Statements

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Robert Uhl

Managing Director, ICR Westwicke

858.356.5932

robert.uhl@westwicke.com

Tom Riga

Chief Executive Officer

949.788.6700

InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals, Inc.

FAQ

What conferences is Spectrum Pharmaceuticals participating in June 2022?

Spectrum Pharmaceuticals will participate in the Jefferies Healthcare Conference on June 9, 2022, and the JMP Securities Life Sciences Conference on June 16, 2022.

Where can I watch the Spectrum Pharmaceuticals investor presentations?

You can watch the live webcasts of the presentations on the Investor Relations section of Spectrum Pharmaceuticals' website.

What is the purpose of Spectrum Pharmaceuticals' presentations at these conferences?

The presentations aim to provide insights on Spectrum's innovative oncology therapies and their business strategy.

What time is the Spectrum presentation at the Jefferies Healthcare Conference?

The presentation at the Jefferies Healthcare Conference is scheduled for June 9, 2022, from 1 to 1:25 p.m. ET.

When will the replay of Spectrum Pharmaceuticals' presentations be available?

A replay of each presentation will be available shortly after the live events.

Spectrum Pharmaceuticals, Inc.

NASDAQ:SPPI

SPPI Rankings

SPPI Latest News

SPPI Stock Data

211.40M
182.70M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link